Understanding the natural progression of a disease is essential for developing effective treatments and establishing reliable endpoints for clinical trials. A recent comprehensive study has provided invaluable insights into the natural history of vision loss in patients with Zellweger Spectrum Disorder (ZSD). By analyzing longitudinal data from a retrospective cohort of 66 patients and reviewing cross-sectional data from 119 patients in the literature, researchers have painted the most detailed picture yet of ophthalmic manifestations in ZSD.
Zellweger Spectrum Disorder is characterized by a wide range of systemic issues, but visual impairment is one of the most consistent and debilitating symptoms across all phenotypes. The study revealed that almost all individuals with ZSD experience retinal degeneration leading to visual impairment, though the onset and severity vary according to the overall disease phenotype. Patients with severe ZSD typically present with worse visual acuity at younger ages compared to those with intermediate or mild forms of the disease. Longitudinal data indicated a slow, progressive loss of visual acuity over time, with the average age of onset for legal blindness occurring at 7.8 years.
Clinical examinations consistently showed retinal pigmentation, macular abnormalities, attenuated vessels, and optic disc changes. Interestingly, these structural abnormalities were more prevalent in milder severity groups and did not significantly change with age, suggesting that the structural damage occurs early in life and remains relatively stable, even as functional vision continues to decline. Electroretinography (ERG) waveforms were diminished in 91% of patients, with nearly half being completely extinguished, highlighting the profound impact of peroxisomal dysfunction on photoreceptor health.
Furthermore, optical coherence tomography (OCT) revealed intraretinal schitic changes—a splitting of the retinal layers—in a significant portion of patients with milder phenotypes. These schitic changes were often accompanied by macular edema, which can further degrade central vision. These findings underscore the complexity of retinal dystrophy in ZSD and demonstrate that serial ERG alone may not be sufficient for documenting disease progression, as the electrical responses often become undetectable long before all functional vision is lost.
Instead, the researchers conclude that multiple systematic measures, including functional vision assessments, visual acuity testing, and advanced imaging like OCT, are required to accurately monitor the disease and evaluate future therapeutic interventions. This natural history study is a crucial step forward, providing the baseline data necessary to design robust clinical trials for emerging treatments, such as gene therapy, aimed at preserving vision in patients with Zellweger Spectrum Disorder.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.